stomatitis; gingivitis; tonsillitis (sore throat); pharyngitis; laryngitis; apply after tooth extraction; apply after removal of the tonsils.
active substance: ambazone;
1 pressed lollipop contains ambazone monohydrate 10 mg;
excipients: sucrose, lactose monohydrate, cocoa, povidone K-30, stearic acid, citric flavor.
Faringosept Dosage form
Main physical and chemical properties: brown, uncoated, cylindrical pressed lollipops, with undamaged edges, flat and with a pigmented surface, with the letter “L” on one side.
Faringosept Pharmacotherapeutic group
Means used in diseases of the throat. Antiseptics. Ambazon.
ATX code R02A A01.
Ambazon is a topical antiseptic that is highly active against pathogenic microorganisms that most commonly cause infections of the oral cavity and upper respiratory tract: streptococci, pneumococci – and also has moderate antistaphylococcal activity. It does not affect the intestinal microflora, therefore, does not cause dysbiosis of the digestive tract.
In addition, the use of pressed lollipops increases salivation and secretion of natural bactericidal substances (such as lysozyme) and at the same time moisturizes the mucous membrane, reduces irritation.
Symptomatic treatment of infections of the oral mucosa and nasopharynx: gingivitis, stomatitis, tonsillitis, sore throat, pharyngitis. Prevention of infectious complications after tonsillectomy and tooth extraction.
Hypersensitivity to any component of the drug.
Interaction with other medicinal products and other forms of interaction
No drug interactions with any other drugs have been reported at this time.
Features of application
Because Faringosept lozenges contain sucrose and lactose, patients with rare hereditary problems of fructose or galactose intolerance, glucose-galactose malabsorption, sucrase-isomaltase insufficiency or lactase deficiency should avoid this medicine. Diabetics should keep in mind that lollipops contain sucrose.
Use during pregnancy or breastfeeding.
There are no controlled clinical trials in the use of ambazone during pregnancy or breastfeeding. However, no evidence of adverse reactions or adverse effects on the fetus has been reported with ambazone during pregnancy. It is not known whether ambazone passes into breast milk.
Faringosept lollipops can be prescribed during pregnancy or breastfeeding only if, in the opinion of the physician, the therapeutic effect for the mother outweighs the potential risk to the fetus.
Ability to influence the speed of reaction when driving a car or other machinery.
The drug does not affect the ability to drive vehicles or work with complex mechanisms.
Method of application and dosage
The recommended dose for adults and children over 7 years of age is 3-5 lollipops (30-50 mg of ambazon) per day for at least 3-4 days. Lollipops should not be swallowed – they should be slowly dissolved in saliva in the mouth. The drug is usually used immediately after a meal (15-30 minutes), after which you should not eat or drink for 2-3 hours.
The recommended dose for children aged 3-7 years – 1 lollipop 3 times a day (30 mg of ambazon per day) for 3-4 days.
Increasing the recommended dose does not improve the therapeutic effect.
Do not use in children under 3 years of age.
To date, no cases of drug overdose have been reported. There is no specific antidote. If a large number of Faringosept lollipops are used, it is recommended to induce vomiting and / or gastric lavage.
Hypersensitivity reactions may occur, including Quincke’s edema, urticaria, pruritus, facial flushing, and rash.